Avaleht › Müeloom › North Carolina › Durham
Müeloom kliinilised uuringud linnas Durham, NC
37 uuringut haiguse Müeloom jaoks otsivad osalejaid linnas Durham ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
VärbamineFaas 3
- Research Site, Chapel Hill · 10 mi kaugusel
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
VärbamineFaas 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mi kaugusel
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
VärbamineFaas 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
VärbamineFaas 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mi kaugusel
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
VärbamineFaas 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi kaugusel
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
VärbamineFaas 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 2
- University of North Carolina Medical Center, Chapel Hill · 10 mi kaugusel
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
VärbamineFaas 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mi kaugusel
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
VärbamineFaas 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi kaugusel
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
VärbamineFaas 1/2
- GSK Investigational Site, Chapel Hill · 10 mi kaugusel
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
VärbamineFaas 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
VärbamineFaas 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
VärbamineFaas 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi kaugusel
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Värbamine
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi kaugusel
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
VärbamineFaas 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
VärbamineFaas 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mi kaugusel
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
VärbamineFaas 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mi kaugusel
Selinexor and Backbone Treatments of Multiple Myeloma Patients
VärbamineFaas 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mi kaugusel
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
VärbamineFaas 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi kaugusel
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
VärbamineFaas 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi kaugusel
Registry of Older Patients With Cancer
VärbamineVaatlusuuring
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi kaugusel
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
VärbamineFaas 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
VärbamineFaas 2
- University of North Carolina, Chapel Hill · 10 mi kaugusel
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
VärbamineFaas 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi kaugusel
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
VärbamineFaas 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mi kaugusel
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
VärbamineFaas 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mi kaugusel
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
VärbamineFaas 1
- University of North Carolina, Chapel Hill · 10 mi kaugusel
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
VärbamineFaas 1
- University of North Carolina, Chapel Hill · 10 mi kaugusel
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
VärbamineFaas 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi kaugusel
Registry for Adults With Plasma Cell Disorders (PCD's)
VärbamineVaatlusuuring
- North Carolina Cancer Hospital, Chapel Hill · 10 mi kaugusel
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
VärbamineVaatlusuuring
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi kaugusel
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
VärbamineFaas 1
- Duke University Health System (DUHS), Durham
Müeloom uuringud teistes linnades
- New York City, NY60 uuringut
- Boston, MA42 uuringut
- Atlanta, GA41 uuringut
- Houston, TX38 uuringut
- Nashville, TN32 uuringut
- Denver, CO27 uuringut
- Rochester, MN24 uuringut
- St. Louis, MO24 uuringut
- Columbus, OH24 uuringut
- Baldwin Park, CA23 uuringut
- Chicago, IL22 uuringut
- Seattle, WA22 uuringut
Muud uuringud linnas Durham
- Rinnavähk63 uuringut
- Vähk (kõik liigid)58 uuringut
- Mitteväikerakuline kopsuvähk39 uuringut
- Metastaatiline vähk33 uuringut
- Äge müeloidne leukeemia33 uuringut
- Kopsuvähk32 uuringut
- Eesnäärmevähk32 uuringut
- Käär- ja pärasoolevähk28 uuringut
- Krooniline lümfotsütaarne leukeemia27 uuringut
- Munasarjavähk27 uuringut
- Südamepuudulikkus26 uuringut
- Pankreasevähk24 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.